Tamarind's announcement describes a $13.6 million fundraise, including a $12 million Series A led by Dimension Capital with participation from Y Combinator. The company frames its focus as infrastructure that lets scientists use molecular AI models without managing cloud and inference systems themselves.
The article describes growth in biotech, pharmaceutical, and academic use, and an expansion from open structure-prediction tools to enterprise models, training, and multi-step pipelines. These figures and customer references are statements from the company's announcement.
The stated direction is to keep supporting open models while building secure, scalable data and inference infrastructure, including organization-specific protocols and models trained on private data. The post also links to company roles and its LinkedIn page.